Survodutide Body Transformation:
Up to 18.7% Weight Loss — Preview with AI
Survodutide (BI 456906) is Boehringer Ingelheim's dual-agonist peptide that boosts metabolism through glucagon activation. See what your body could look like at 1, 3, 6, or 12 months.
Key Takeaways (SYNCHRONIZE-1 Phase 3 Data)
- Average weight loss on survodutide 4.8mg: 18.7% of body weight over 46 weeks
- Extension data showed up to ~20% weight loss with continued treatment
- Dual agonist mechanism targets GLP-1 and Glucagon receptors simultaneously
- Glucagon activation boosts metabolism and fat burning — especially liver fat reduction
- Developed by Boehringer Ingelheim — currently in Phase 3 clinical trials
What Is Survodutide?
Survodutide (BI 456906) is a dual GLP-1/Glucagon receptor agonist developed by Boehringer Ingelheim. Unlike semaglutide (Ozempic), which targets only GLP-1 receptors, survodutide activates two complementary pathways:
- GLP-1 (Glucagon-Like Peptide-1) — Reduces appetite, slows gastric emptying, and improves blood sugar control
- Glucagon — Increases energy expenditure, promotes fat oxidation, and targets liver fat reduction
This dual mechanism sets survodutide apart: while GLP-1 suppresses appetite, the glucagon component actively accelerates metabolism and fat burning. This combination is particularly effective at reducing liver fat, making survodutide a promising treatment for both obesity and metabolic liver disease (MASH/NASH).
Survodutide Weight Loss Timeline
Based on SYNCHRONIZE-1 Phase 3 trial data, here is the expected weight loss timeline for someone starting at 220 lbs on the 4.8mg dose:
| Timeline | Expected Weight Loss | Visual Changes |
|---|---|---|
| Month 1 | 3-6 lbs (1-3%) | Reduced bloating, early appetite suppression |
| Month 3 | 12-22 lbs (5-10%) | Visible face slimming, clothes fitting looser |
| Month 6 | 25-40 lbs (11-18%) | Dramatic body shape change, defined jawline, new wardrobe needed |
| Month 12 | 35-48 lbs (16-22%) | Sustained transformation, significant metabolic improvements |
Survodutide vs. Ozempic vs. Mounjaro: Head-to-Head
Survodutide's unique dual GLP-1/Glucagon mechanism delivers competitive weight loss with distinct metabolic advantages, particularly in liver fat reduction and energy expenditure.
| Metric | Ozempic | Mounjaro | Survodutide |
|---|---|---|---|
| Avg weight loss | 14.9% | 22.5% | 18.7% |
| Max observed | ~17% | ~25% | ~20% |
| Mechanism | GLP-1 | GLP-1 + GIP | GLP-1 + Glucagon |
| Key trial | STEP-1 | SURMOUNT-1 | SYNCHRONIZE-1 |
| Manufacturer | Novo Nordisk | Eli Lilly | Boehringer Ingelheim |
| FDA status | Approved | Approved | Phase 3 |
Use our GLP-1 & Peptide Weight Loss Calculator to compare projected timelines for all medications based on your starting weight.
Survodutide Dosing Schedule
Survodutide is administered as a once-weekly subcutaneous injection. The dose escalation schedule from the SYNCHRONIZE-1 trial:
| Weeks | Dose | Phase |
|---|---|---|
| Weeks 1-4 | 0.6 mg | Initiation |
| Weeks 5-8 | 1.2 mg | Escalation |
| Weeks 9-12 | 2.4 mg | Escalation |
| Weeks 13-16 | 3.6 mg | Escalation |
| Week 17+ | 4.8 mg | Target / Maintenance |
Frequently Asked Questions
How much weight can you lose on survodutide?
In the Phase 3 SYNCHRONIZE-1 trial, participants on survodutide 4.8mg lost an average of 18.7% of their body weight over 46 weeks. In the extension study, weight loss reached approximately 20%. These results exceed those of semaglutide (Ozempic) and position survodutide as a strong next-generation option for weight management.
Is survodutide better than Ozempic?
Clinical data suggests survodutide produces greater weight loss (18.7%) than semaglutide (Ozempic, 14.9%). The key differentiator is the mechanism: survodutide's dual GLP-1/Glucagon action provides both appetite suppression and increased energy expenditure. Ozempic targets only GLP-1. However, survodutide is not yet FDA-approved, and direct head-to-head trials have not been completed.
When will survodutide be available?
Survodutide is currently in Phase 3 clinical trials as part of the SYNCHRONIZE program conducted by Boehringer Ingelheim. If trials are successful and FDA approval is granted, survodutide could potentially become available by 2027. Until then, you can preview your potential results with BeforeAfterFit's AI visualization tool.
What makes survodutide different from other weight loss drugs?
Survodutide is unique because it combines GLP-1 and glucagon receptor activation. While GLP-1 reduces appetite and slows gastric emptying, the glucagon component actively boosts metabolism and promotes fat burning — particularly targeting liver fat. This dual mechanism differentiates it from single-agonist drugs like Ozempic (GLP-1 only) and dual-agonist drugs like Mounjaro (GLP-1/GIP). Survodutide is the only advanced-stage drug combining GLP-1 with glucagon rather than GIP.
Related Resources
Medical Disclaimer: BeforeAfterFit is a visualization and motivation tool only. It does not provide medical advice. Survodutide (BI 456906) is not FDA-approved for weight loss and is currently in Phase 3 clinical trials. Clinical trial results may not reflect individual outcomes. Always consult your healthcare provider before starting any medication.